{"schema_version":"secwatch.filing_event.v1","accession":"0001737287-25-000087","form_type":"8-K","ticker":"ALLO","cik":"0001737287","company_name":"Allogene Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.840535+00:00","generated_at":"2026-05-17T13:57:47.900208+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Allogene Q2 net loss $50.9M; highlights ALPHA3 trial progress and ALLO-329 autoimmune initiation","bullets":["Net loss of $50.9M ($0.23/share) for Q2 2025; cash and investments $302.6M as of June 30, 2025.","Pivotal ALPHA3 trial for cema-cel in LBCL proceeding as randomized two-arm study; futility analysis on track for 1H 2026.","Phase 1 RESOLUTION trial with ALLO-329 initiated in rheumatology autoimmune diseases; proof-of-concept data expected 1H 2026.","ALLO-316 completed Phase 1b enrollment in RCC; FDA aligned on pivotal trial design, partnership discussions possible.","Cash runway projected into 2H 2027; 2025 guidance: cash burn ~$150M, GAAP OpEx ~$230M."],"urls":{"canonical":"https://secwatch.observer/filing/0001737287-25-000087","json":"https://secwatch.observer/filing/0001737287-25-000087.json","markdown":"https://secwatch.observer/filing/0001737287-25-000087.md","text":"https://secwatch.observer/filing/0001737287-25-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737287/000173728725000087/0001737287-25-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737287/000173728725000087/allo-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:47.900208+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}